Key result
Systematic review evaluates adding statins and aspirin to ART for reducing cardiac events in HIV.
Why the study?
Antiretroviral therapy improves quality of life in HIV patients but is associated with increased cardiovascular disease risk, and the effects of adding aspirin and statins to ART on cardiac events require evaluation.
Does the addition of aspirin and statins to antiretroviral therapy reduce cardiac adverse events in HIV patients with cardiovascular disease?
Systematic Review
Does the addition of aspirin and statins to antiretroviral therapy reduce cardiac adverse events in HIV patients with cardiovascular disease?
This systematic review aims to evaluate the efficacy and potential drug interactions of adding statins and aspirin to antiretroviral therapy for cardiovascular risk reduction in HIV patients.
May guide statin-aspirin addition in HIV-CVD on ART; extends evidence on efficacy and interactions.
Globally, the incidence of newly diagnosed human immunodeficiency virus (HIV) infections is concerning. Despite enhancing the quality of life for this patient population, antiretroviral therapy (ART) is linked to an increased risk of cardiovascular disease (CVD). In people living with HIV (PLWH) undergoing ART, recent research has demonstrated that the use of statins and aspirin (ASA) can reduce the incidence or progression of CVD. However, research has demonstrated that interactions may occur when these medications are used concurrently in the treatment regimen of PLWH. Therefore, we conclude this systematic review to evaluate the use of ART in HIV individuals with CVD and also the effect of adding ASA and statins to ART for reducing the cardiac adverse events.
No takes yet. Share an insight, caveat, or question.
Azad Mojahedi (2024) conducted a systematic review in HIV and cardiovascular disease. Antiretroviral therapy (ART) with statins and aspirin was evaluated on Cardiac adverse events. This systematic review evaluates the efficacy and potential drug interactions of adding statins and aspirin to antiretroviral therapy for reducing cardiac adverse events in HIV patients with CVD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: